NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SAKAR · data 2026-10-31
Sakar Healthcare Ltd
In plain words
Price: 23.2% below its 52-week high of ₹1,229.85.
Delivery: 40.4% of traded shares were kept for delivery over the last 10 sessions, against 46.6% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹302 cr |
| Net profit (last 12 months) | ₹43 cr |
| Sales growth, 3 years (yearly) | 23.6% |
| Profit growth, 3 years (yearly) | 33.7% |
At a glance
Promoters 51.7% (-1.2 pts in a year), pledged 0.0%, institutions 24.3%.
P/E 49.0, P/B 6.1, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 10.0%, ROCE 12.4%, operating margin 21.5%: how much profit it earns on the money it uses.
Debt/equity 0.17, Profit growth 33.7% and sales growth 23.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (21.5%).
- Profit grew 33.7% a year over 3 years.
- Promoters cut their holding by 1.2 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 38.8% over the last 20 sessions vs 40.4% in the 40 before (0.96x); shares delivered per day 1.02x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.70% | 52.52% | 52.86% | 52.86% |
| Foreign institutions (FII) | 12.34% | 12.13% | 12.94% | 13.05% |
| Domestic institutions (DII) | 11.92% | 11.37% | 11.32% | 11.36% |
| Mutual funds | — | — | — | — |
| Retail investors | 17.09% | 16.06% | 12.49% | 10.90% |
| Number of shareholders | 19,539 | 14,734 | 9,580 | 7,069 |
Common questions
How much do promoters hold in Sakar Healthcare Ltd?
Promoters held 51.70% of Sakar Healthcare Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sakar Healthcare Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.17.
What is Sakar Healthcare Ltd's P/E ratio?
About 49, based on the last 12 months' earnings and a price of ₹944.8 (data 2026-10-31).
What is the 52-week high and low of Sakar Healthcare Ltd?
The 52-week high is ₹1,229.85 and the 52-week low is ₹352.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sakar Healthcare Ltd | ₹944.8 | ₹2,074 cr | 49 | 6.1 | 10% | 12.4% | 0.17 | +167.0% |
| Alembic Limited | ₹87.22 | ₹2,239 cr | 7 | — | 13.3% | 3.3% | 0 | -13.2% |
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
Compare SAKAR with ALEMBICLTD in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SAKAR in NSE Scanner →